Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07201558 · ClinicalTrials.gov registry record · Phase 1

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

A Phase 1 study of Rheumatoid Arthritis and Systemic Lupus Erythematosus, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
48
Enrollment target
19
Study locations

NCT07201558: Recruiting Phase 1 study of Rheumatoid Arthritis and Systemic Lupus Erythematosus, sponsored by AstraZeneca.

NCT07201558 is a Phase 1 study of Rheumatoid Arthritis and Systemic Lupus Erythematosus that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 48 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 19 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07201558, a Phase 1 study of Rheumatoid Arthritis and Systemic Lupus Erythematosus, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
48 participants
Enrollment target
19
Study locations

Study Summary

This open-label, Phase I study will assess the safety and tolerability of surovatamig and characterise its PK and PD following subcutaneous administration to participants with RA or SLE.

Primary Outcome

Number and percentage of participants with adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)

Interventions

  • BIOLOGICAL Surovatamig

Study Locations (19)

Other

  • Research Site - Birtinya
  • Research Site - Clayton
  • Research Site - Antwerp
  • Research Site - Porto Alegre
  • Research Site - Beijing
  • Research Site - Nanjing
  • Research Site - Bonn
  • Research Site - Mainz
  • Research Site - München
  • Research Site - Barcelona
  • Research Site - Córdoba
  • Research Site - Madrid
  • Research Site - Kaohsiung City
  • Research Site - Kyiv
  • Research Site - Ternopil
  • Research Site - Vinnytsia

Alabama

  • Research Site - Birmingham

California

  • Research Site - Fullerton

Texas

  • Research Site - Allen

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2025-12-02
Est. Completion 2028-06-27
Phase Phase 1
AstraZeneca

1,285 total trials

What NCT07201558 shows while recruiting

NCT07201558 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Surovatamig is the first listed.

NCT07201558 lists 19 locations in 4 states (Other, Alabama, California).

Frequently Asked Questions

What is clinical trial NCT07201558 about?

NCT07201558 is a clinical study titled "Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants". This open-label, Phase I study will assess the safety and tolerability of surovatamig and characterise its PK and PD following subcutaneous administration to participants with RA or SLE.

What is the current status of trial NCT07201558?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-12-02. Estimated completion is 2028-06-27.

What conditions does trial NCT07201558 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis, Systemic Lupus Erythematosus.

What interventions are being tested in trial NCT07201558?

The interventions under investigation include: Surovatamig (BIOLOGICAL).

Who is sponsoring clinical trial NCT07201558?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07201558 being conducted?

This trial has 19 study locations across Alabama, California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07201558's enrollment target sits among peer trials

48 143rd of 197 higher than 54 of 197 other Rheumatoid Arthritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07201558, the US trial registry maintained by the National Library of Medicine. NCT07201558 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.